Last reviewed · How we verify
Cabotegravir Injection [Apretude]
Cabotegravir Injection [Apretude] is a marketed drug developed by the University of Witwatersrand, South Africa, with a key composition patent expiring in 2028. Its primary strength lies in its unique mechanism of action, which differentiates it in the market. The primary risk is the lack of revenue data and key trial results, which may limit its competitive positioning and investor confidence.
At a glance
| Generic name | Cabotegravir Injection [Apretude] |
|---|---|
| Also known as | Apretude |
| Sponsor | University of Witwatersrand, South Africa |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: